CAJ | 학술논문

肠促胰素作为新型糖尿病治疗药物已在2型糖尿病中得到了广泛应用,其疗效及安全性也已得到证实,然而,在1型糖尿病中的研究相对较少. 目前已有多项临床研究显示肠促胰素也可以有效改善血糖控制.本文将结合动物实验,从临床研究方面对肠促胰素在1型糖尿病中的临床应用进行评论.
장촉이소작위신형당뇨병치료약물이재2형당뇨병중득도료엄범응용,기료효급안전성야이득도증실,연이,재1형당뇨병중적연구상대교소. 목전이유다항림상연구현시장촉이소야가이유효개선혈당공제.본문장결합동물실험,종림상연구방면대장촉이소재1형당뇨병중적림상응용진행평론.
Incretin-based therapies are now being widely used in type 2 diabetes as a new type of antidiabetic drugs,with their efficacy and safety having been confirmed.However,there are relatively few researches carried out in type 1 diabetes.A variety of clinical studies (mainly in type 2 diabetes) have shown that incretin-based therapy could effectively improve glucose control.In this article,the clinieal application of incretin-based therapy in type 1 diabetes will be reviewed and commented from the prospective of clinical studies,combined with animal experiments.